Disability profiles and objective quantitative assessment in Parkinson's disease.
A new technique for quick objective and quantitative determination of important aspects of the motor handicap in movement disorders is presented. A compound, but natural, test movement was used to find out if the degree of dysfunction in postural, locomotor and manual motor functions differed among the patients and if medication influenced these functions differently. After 12 h without medication, 16 patients with Parkinson's disease showed a movement time between 1.5 and 13.6 times that of an age-matched normal subject and a greater performance variability on repeated examination. In some patients the increase of test movement time was caused mainly by the locomotion component while in others the time for the postural or manual part of the movement was more markedly augmented. Thus, a specific motor disability profile was found for each patient and expressed in quantitative terms. The effects of l-dopa treatment were quantified in each patient.
Johnels
B
B
Department of Neurology, University of Gothenburg, Sweden.
Ingvarsson
P E
PE
Thorselius
M
M
Valls
M
M
Steg
G
G
D000328:Adult; D000368:Aged; D001545:Benserazide / Q000627:therapeutic use; D002230:Carbidopa / Q000627:therapeutic use; D004185:Disability Evaluation; D004338:Drug Combinations / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D008124:Locomotion / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000175:diagnosis* / Q000188:drug therapy; D011187:Posture / Q000187:drug effects; D011597:Psychomotor Performance / Q000187:drug effects; D011930:Reaction Time / Q000187:drug effects
D004338:Drug Combinations; C005177:benserazide, levodopa drug combination; C009265:carbidopa, levodopa drug combination; D007980:Levodopa; D001545:Benserazide; D002230:Carbidopa